Epirubicin and Liver Tests in Breast Cancer
Author Information
Author(s): C.J. Twelves, N.A. Dobbs, Y. Michael, L.A. Summers, W. Gregory, P.G. Harper, R.D. Rubens, M.A. Richards
Primary Institution: Imperial Cancer Research Fund Clinical Oncology Unit, United Medical and Dental Schools; Department of Medical Oncology, Guy's Hospital
Hypothesis
The study investigates the influence of liver biochemistry tests on the pharmacokinetics of epirubicin in women with advanced breast cancer.
Conclusion
A raised serum AST is a more sensitive and reliable measure of abnormal epirubicin pharmacokinetics than increased bilirubin.
Supporting Evidence
- Epirubicin clearance was significantly reduced in patients with raised AST.
- AST was the only biochemical variable predictive of epirubicin clearance.
- Patients with normal liver tests had higher epirubicin clearance.
Takeaway
This study shows that checking a specific liver test (AST) is better for understanding how a cancer drug (epirubicin) works in patients with liver issues.
Methodology
Patients received epirubicin as an intravenous bolus, and pharmacokinetics were studied by measuring drug levels in blood samples over 48 hours.
Limitations
The study did not include patients with prior anthracycline treatment or those taking drugs affecting liver function.
Participant Demographics
52 women with advanced breast cancer, divided into groups based on liver function tests.
Statistical Information
P-Value
0.0006
Statistical Significance
p=0.0006
Want to read the original?
Access the complete publication on the publisher's website